Janice Drew

946 total citations · 1 hit paper
21 papers, 684 citations indexed

About

Janice Drew is a scholar working on Physiology, Immunology and Dermatology. According to data from OpenAlex, Janice Drew has authored 21 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 7 papers in Immunology and 5 papers in Dermatology. Recurrent topics in Janice Drew's work include Sympathectomy and Hyperhidrosis Treatments (11 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Dermatology and Skin Diseases (5 papers). Janice Drew is often cited by papers focused on Sympathectomy and Hyperhidrosis Treatments (11 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Dermatology and Skin Diseases (5 papers). Janice Drew collaborates with scholars based in United States, Germany and Belgium. Janice Drew's co-authors include Andrew Blauvelt, Ramanan Gopalan, Lawrence F. Eichenfield, Amy S. Paller, April W. Armstrong, Emma Guttman‐Yassky, Eric L. Simpson, Luke Peterson, Daniel Burge and David M. Pariser and has published in prestigious journals such as Journal of the American Academy of Dermatology, Clinical Pharmacokinetics and Journal of Surgical Research.

In The Last Decade

Janice Drew

20 papers receiving 671 citations

Hit Papers

Efficacy and Safety of Lebrikizumab, a High-Affinity Inte... 2020 2026 2022 2024 2020 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
    2020 248 citations Emma Guttman‐Yassky, Andrew Blauvelt et al. JAMA Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janice Drew United States 12 401 273 263 188 151 21 684
Nicole Dumont United States 12 329 0.8× 285 1.0× 89 0.3× 115 0.6× 102 0.7× 21 531
Jorge R. Georgakopoulos Canada 11 261 0.7× 211 0.8× 90 0.3× 84 0.4× 71 0.5× 42 388
Alexandra Gruber‐Wackernagel Austria 15 487 1.2× 403 1.5× 94 0.4× 48 0.3× 42 0.3× 28 690
H.M. Ockenfels Germany 15 336 0.8× 235 0.9× 57 0.2× 57 0.3× 62 0.4× 33 519
Irina Turchin Canada 13 256 0.6× 170 0.6× 63 0.2× 64 0.3× 83 0.5× 44 424
M. Ruer‐Mulard France 7 288 0.7× 376 1.4× 55 0.2× 49 0.3× 68 0.5× 18 522
D. Toth Canada 5 565 1.4× 555 2.0× 193 0.7× 193 1.0× 146 1.0× 6 800
Tianshuang Wu United States 9 483 1.2× 395 1.4× 174 0.7× 189 1.0× 152 1.0× 21 735
M.T. Guinnepain France 11 227 0.6× 122 0.4× 122 0.5× 280 1.5× 223 1.5× 34 776
Gaia Moretta Italy 12 244 0.6× 275 1.0× 81 0.3× 41 0.2× 42 0.3× 34 401

Countries citing papers authored by Janice Drew

Since Specialization
Citations

This map shows the geographic impact of Janice Drew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janice Drew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janice Drew more than expected).

Fields of papers citing papers by Janice Drew

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janice Drew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janice Drew. The network helps show where Janice Drew may publish in the future.

Co-authorship network of co-authors of Janice Drew

This figure shows the co-authorship network connecting the top 25 collaborators of Janice Drew. A scholar is included among the top collaborators of Janice Drew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janice Drew. Janice Drew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pariser, David M., Edward Lain, Richard D. Mamelok, Janice Drew, & Diane R. Mould. (2021). Limited Systemic Exposure with Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis. Clinical Pharmacokinetics. 60(5). 665–676. 7 indexed citations
2.
3.
Guttman‐Yassky, Emma, Andrew Blauvelt, Lawrence F. Eichenfield, et al.. (2020). Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis. JAMA Dermatology. 156(4). 411–411. 248 indexed citations breakdown →
4.
Glaser, Dee Anna, Adelaide A. Hebert, Alexander Nast, et al.. (2019). A 44-Week Open-Label Study Evaluating Safety and Efficacy of Topical Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis. American Journal of Clinical Dermatology. 20(4). 593–604. 21 indexed citations
5.
Nelson, Lauren, Dana DiBenedetti, David M. Pariser, et al.. (2019). Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity. Journal of Patient-Reported Outcomes. 3(1). 59–59. 12 indexed citations
6.
Guttman‐Yassky, Emma, Andrew Blauvelt, Lawrence F. Eichenfield, et al.. (2019). Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study. SKIN The Journal of Cutaneous Medicine. 3. S41–S41. 4 indexed citations
7.
Glaser, Dee Anna, Adelaide A. Hebert, Alexander Nast, et al.. (2018). Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. Journal of the American Academy of Dermatology. 80(1). 128–138.e2. 46 indexed citations
8.
Lebwohl, Mark, Andrew Blauvelt, C. Paul, et al.. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). Journal of the American Academy of Dermatology. 79(2). 266–276.e5. 101 indexed citations
9.
Pariser, David M., Adelaide A. Hebert, Janice Drew, et al.. (2018). Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials. American Journal of Clinical Dermatology. 20(1). 135–145. 25 indexed citations
10.
Glaser, Dee Anna, Adelaide A. Hebert, Alexander Nast, et al.. (2018). Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Primary Axillary Hyperhydrosis. SKIN The Journal of Cutaneous Medicine. 2. S40–S40.
11.
Gottlieb, Alice B., Andrew Blauvelt, Diamant Thaçi, et al.. (2018). Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). Journal of the American Academy of Dermatology. 79(2). 302–314.e6. 121 indexed citations
12.
Hebert, Adelaide A., Dee Anna Glaser, Lawrence Green, et al.. (2018). Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: Post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials. Pediatric Dermatology. 36(1). 89–99. 16 indexed citations
13.
Blauvelt, Andrew, Kristian Reich, Mark Lebwohl, et al.. (2018). Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. Journal of the European Academy of Dermatology and Venereology. 33(3). 546–552. 30 indexed citations
14.
Piguet, Vincent, Andrew Blauvelt, Daniel Burge, et al.. (2017). Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT). SKIN The Journal of Cutaneous Medicine. 1. s3–s3. 1 indexed citations
15.
Glaser, Dee Anna, Adelaide A. Hebert, Alexander Nast, et al.. (2017). Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis. SKIN The Journal of Cutaneous Medicine. 1. s95–s95. 2 indexed citations
16.
Thaçi, Diamant, Alice B. Gottlieb, Kristian Reich, et al.. (2017). Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 1. s4–s4. 1 indexed citations
17.
18.
Glaser, Dee Anna, Adelaide A. Hebert, Sheri Fehnel, et al.. (2017). Confirmatory Psychometric Evaluation of the Axillary Sweating Daily Diary: A Vaildated Patient-Reported Outcome Measure to Assess Axillary Hyperhidrosis Sweating Severity. SKIN The Journal of Cutaneous Medicine. 1. s94–s94. 4 indexed citations
19.
Bissonnette, Robert, Yves Poulin, Janice Drew, Hans Hofland, & Jerry Tan. (2016). Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study. Journal of the American Academy of Dermatology. 76(1). 33–39. 20 indexed citations
20.
Sankary, Howard, Eric B. Rypins, Kenneth Waxman, et al.. (1987). Effects of portacaval shunt and hepatic artery ligation on liver surface oxygen tension and effective hepatic blood flow. Journal of Surgical Research. 42(1). 7–9. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole Dumont Breakdown of academic impact, for papers by Jorge R. Georgakopoulos Breakdown of academic impact, for papers by Alexandra Gruber‐Wackernagel Breakdown of academic impact, for papers by H.M. Ockenfels Breakdown of academic impact, for papers by Irina Turchin Breakdown of academic impact, for papers by M. Ruer‐Mulard Breakdown of academic impact, for papers by D. Toth Breakdown of academic impact, for papers by Tianshuang Wu Breakdown of academic impact, for papers by M.T. Guinnepain Breakdown of academic impact, for papers by Gaia Moretta
Rankless by CCL
2026